SignalXSignalX

CELC Celcuity Inc.

Q3 2025 10-Q
Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Services-Medical LaboratoriesSEC EDGAR
Celcuity Inc. Overview

Celcuity Inc. (CELC) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: increased tariffs and trade policy uncertainty due to U.S. changes triggering retaliatory foreign actions and exemptions increasing cost volatility
  • • Most updated regulatory risk: FDA leadership loss and funding cuts raising timing and approval uncertainties for drug applications and clinical guidance
+3 more insights

Quarterly Financial Summary
XBRL

Net Income

-$44M

ROE

-37.5%

Total Assets

$476M

Source: XBRL data from Celcuity Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Celcuity Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.